Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis

Supportive Care in Cancer

Volumn 22, Issue 8, 2014, Pages 2271-2280

  McGinty, Heather L ^a,b   Phillips, Kristin M ^c   Jim, Heather S L ^b   Cessna, Julie M ^a,b   Asvat, Yasmin ^a,b   Cases, Mallory G ^b   Small, Brent J ^a,b   Jacobsen, Paul B ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Androgen deprivation therapy; Cognition; Meta analysis; Neuropsychological tests; Prostatic neoplasms; Systematic review

Indexed keywords

ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ATTENTION; CANCER HORMONE THERAPY; CANCER PATIENT; COCHRANE LIBRARY; COGNITION; DEPTH PERCEPTION; EFFECT SIZE; EXECUTIVE FUNCTION; FOLLOW UP; HUMAN; LANGUAGE; MALE; MEDLINE; META ANALYSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSTATE CANCER; PSYCINFO; REVIEW; SYSTEMATIC REVIEW; VERBAL MEMORY; VISUAL MEMORY; VISUOMOTOR COORDINATION; WORKING MEMORY;

ANDROGEN ANTAGONISTS; COGNITION; COGNITION DISORDERS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PROSTATIC NEOPLASMS;

EID: 84905115863     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2285-1     Document Type: Review

References (41)

1. National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology version 2: 2013 Prostate cancer information. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed 01 June 2013
2. Alibhai SMH, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60: 201-215. doi:10.1016/j.critrevonc.2006.06.006 (Pubitemid 44709617)
3. Akaza H (2011) Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 102:51-56. doi:10.1111/j.1349-7006.2010.01774.x
4. Kumar R, Barqawi A, Crawford ED (2005) Preventing and treating the complications of hormone therapy. Curr Urol Rep 6:217-223. doi:10.1007/s11934- 005-0010-9
5. Holland J, Bandelow S, Hogervorst E (2011) Testosterone levels and cognition in elderly men: a review. Maturitas 69:322-337. doi:10.1016/j. maturitas.2011.05.012
6. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM (2002) Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderlymen. J Clin Endocrinol Metab 87:5001-5007. doi:10.1210/jc.2002-020419 (Pubitemid 35316338)
7. Thilers PP, MacDonald SWS, Herlitz A (2006) The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 31:565-576. doi:10.1016/j.psyneuen.2005.12.005
8. Linn MC, Petersen AC (1985) Emergence and characterization of sex differences in spatial ability: a meta-analysis. Child Dev 56:1479-1498. doi:10.2307/1130467
9. Voyer D, Voyer S, Bryden MP (1995) Magnitude of sex differences in spatial abilities: a meta-analysis and consideration of critical variables. Psychol Bull 117:250-270. doi:10.1037/0033-2909.117.2.250
10. Nelson CJ, Lee JS, Gamboa MC, Roth AJ (2008) Cognitive effects of hormone therapy in men with prostate cancer. Cancer 113:1097-1106. doi:10.1002/cncr. 23658
11. Jamadar RJ, Winters MJ, Maki PM (2012) Cognitive changes associated with ADT: a review of the literature. Asian J Androl 14:232-238. doi:10.1038/aja. 2011.107
12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264-269. doi:10.1371/journal.pmed.1000097
13. Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment, 4th edn. Oxford University Press, New York
14. Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, San Diego
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188. doi:10.1016/0197-2456(86)90046-2 (Pubitemid 17189972)
16. Orwin RG (1983) A fail-safe N for effect size in meta-analysis. J Educ Stat 8:157-159
17. Salminen E, Portin R, Korpela J, Backman H, Parvinen L-M, Helenius H, Nurmi M (2003) Androgen deprivation and cognition in prostate cancer. Br J Cancer 89:971-976. doi:10.1038/sj.bjc.6601235 (Pubitemid 37239197)
18. Alibhai SMH, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, Naglie G et al (2010) Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol 28:5030-5037. doi:10.1200/JCO.2010.30.8742
19. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, MacTaggart PN, Swanson CE et al (2002) Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90:427-432. doi:10.1046/j.1464- 4096.2002.02917.x (Pubitemid 36124778)
20. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, MacTaggart PN, Swanson CE et al (2004) Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93:975-979. doi:10.1111/j.1464-410X.2004. 04763.x (Pubitemid 38758617)
21. Matousek RH, Sherwin BB (2010) A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology 35:215-225. doi:10.1016/j.psyneuen.2009.06.012
22. Cherrier MM, Borghesani PR, Shelton AL, Higano CS (2010) Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer 10:1-8. doi:10.1186/1471-2407-10-1
23. Bussiere JR, Beer TM, Neiss MB, Janowsky JS (2005) Androgen deprivation impairs memory in older men. Behav Neurosci 119:1429-1437. doi:10.1037/0735- 7044.119.6.1429 (Pubitemid 43145715)
24. Clay CA, Perera S, Wagner JM, Miller ME, Nelson JB, Greenspan SL (2007) Physical function inmen with prostate cancer on androgen deprivation therapy. Phys Ther 87:1325-1333. doi:10.2522/ptj.20060302 (Pubitemid 47584278)
25. Jim HSL, Small BJ, Patterson S, Salup R, Jacobsen PB (2010) Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer 18:21-27. doi:10.1007/s00520-009-0625-3
26. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN (2004) One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29:1071-1081. doi:10.1016/j.psyneuen.2003.11.002 (Pubitemid 38833535)
27. Cherrier MM, Rose AL, Higano C (2003) The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170:1808-1811. doi:10.1097/01.ju.0000091640.59812.83 (Pubitemid 37254933)
28. Cherrier MM, Aubin S, Higano CS (2009) Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 18:237-247. doi:10.1002/pon.1401
29. Jenkins VA, Bloomfield DJ, Shilling VM, Edington TL (2005) Does neoadjuvant hormone therapy for early prostate cancer affect cognition? results from a pilot study. BJU Int 96:48-53. doi:10.1111/j.1464-410X.2005.05565.x (Pubitemid 40942867)
30. Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stradler WM (2010) Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. J Geriatr Oncol 1:13-19. doi:10.1016/j.critrevonc. 2010.06.009
31. Galvao DA, Joseph D, Spry N, Joseph D, Turner D, Newton RU (2008) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12:198-203. doi:10.1038/pcan.2008.51
32. Smith MR, Finkelstein JS, McGovern FJ, Zeitman AL, Fallon MA, Schoenfeld DA, Kantoff PW (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603 (Pubitemid 34158224)
33. Smith MR (2004) Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63:742-745. doi:10.1016/j.urology.2003.10.063
34. Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M et al (2008) Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 72:422-427. doi:10.1016/j.urology.2008.03.032
35. Anderson-Hanley CAY, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967-982. doi:10.1017/S1355617703970019 (Pubitemid 37428441)
36. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222-2233. doi: 10.1002/cncr.21469 (Pubitemid 41579970)
37. Jim HSL, Phillips KM, Chait S, Faul LA, Popa MA, Lee Y-M, Hussin MG et al (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587. doi:10.1200/JCO.2011.39.5640
38. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ et al (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110:143-152. doi:10.1007/s10549-007- 9686-5 (Pubitemid 351793851)
39. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG et al (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32:324-331. doi:10.1080/ 13803390903032537
40. Meyers CA, Byrne KS, Komaki R (1995) Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231-235
41. Schagen SB, van Dam FSAM (2006) Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? J Clin Oncol 24:5170-5171. doi:10.1200/JCO.2006.07.8303 (Pubitemid 46623205)